A composition capable of reducing uric acid, dissolving uric acid crystals and tophi and application thereof

Abstract

The present invention provides a composition for lowering uric acid, dissolving uric acid crystals and tophi, and application thereof. The composition comprises a probiotic composition and prebiotics; wherein, the probiotic composition is Lactobacillus reuteri, One or more of Lactobacillus fermentum, Bacillus coagulans, Lactobacillus rhamnosus, Lactobacillus casei and Lactobacillus plantarum, the mass ratio of the probiotic composition and the prebiotic is (1-80): (1-80 ). By combining the probiotic composition and prebiotics, the prepared compound bacteria powder can significantly reduce the blood uric acid of gout patients, and the crystal dissolving effect of the compound bacteria powder is verified by dual-energy CT for the first time.

Description

technical field [0001] The present invention relates to the technical field of prevention and treatment of hyperuricemia and gout, and more particularly, to a composition capable of lowering uric acid, dissolving uric acid crystals and tophi, and application thereof. Background technique [0002] Gout is a crystal-related arthropathy caused by the deposition of monosodium urate. It is directly related to hyperuricemia caused by disturbance of purine metabolism and decreased uric acid excretion. It belongs to the category of metabolic rheumatism. The clinical symptoms of gout are severe pain, edema, redness, and inflammation of the joints. The first attack usually involves a single joint, the most common is the first metatarsophalangeal joint, and subsequent attacks can involve the dorsum of the foot, ankle, heel, knee, and wrist. Gout, fingers, elbows and other joints, with fever; 3-14% of patients with multiple joints involved in the first attack; acute gout rarely involves...

AI Technical Summary

Problems solved by technology

However, the above-mentioned drugs cannot solve the fundamental cause of these gouts, they can only simply inhibit the activity of xanthine oxidase, inhibit the reabsorption capacity of URAT1, increase the secretion activity of ABCG2, and degrade blood uric acid; moreover, these drugs dissolve the deposited uric acid Crystals and tophi have harsh conditions, and it is necessary to keep blood uric acid below 360 μmol / L; in addition, these drugs have great damage to the liver and kidneys, and cannot be used more often or for a long time. Many patients give up using this drug because they cannot bear the side effects. drugs for treatment

Images